All News
Variable Pregnancy Outcomes with Belimumab in SLE
An analysis of the belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports looked at outcomes in pregnant systemic lupus erythematosus (SLE) exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to
Read Article
Links:
JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure?
Data from 17 international registries (JAK-pot collaboration) suggest that for Rheumatoid arthritis (RA) patients failing their first janus kinase inhibitor (JAKi), it did not matter if they were cycled to another JAKi or switched to a biologic disease-modifying antirheumatic drug (bDMARD).
Read Article
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients
Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the American College of Rheumatology (ACR), though the timing for their administration and dosing of antirheumatic drugs may need adjustment in some cases.
Read Article
Links:
Links:
Links:
Links:
2022 Rheumatology Year in Review (1-6-2023)
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
Read Article
Links:
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
In Giant Cell Arteritis, Hospital Admission Is Bad News
One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.
Read Article
Links:
Links:
Links:
Best of 2022: New Updated GRAPPA Psoriatic Arthritis Recommendations
The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail psoriasis; with new PsA related domains uveitis and inflammatory bowel disease.
Read Article
Best of 2022: EULAR 2022 Top 10 Abstracts
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
Read Article
Best of 2022: Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi). Dermatologists often refer to this side effect as "JAKne".
Read Article